Elizabeth Smyth, MD, on New Data in Gastric/Gastroesophageal Cancers
ASCO 2026
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007).
The ASCO Post Staff
Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center, describes the safety and efficacy results of the all-oral first-line combination regimen of sonrotoclax and zanubrutinib for patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), as well as the doublet’s effect on measurable residual disease (Abstract 7043). He also discusses the phase III BGB-11417-304/CELESTIAL-TNCLL-2 trial; this ongoing study is evaluating sonrotoclax plus zanubrutinib vs venetoclax and acalabrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) (Abstract TPS7099).
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527).
Wassim McHayleh, MD, FACP, MBA, of AdventHealth Cancer Institute, provides an update from the phase Ib/II ELEVATE trial, an open-label umbrella study. This report focuses on updated safety and preliminary efficacy for elacestrant and capivasertib for patients with estrogen receptor (ER)-positive/HER2-negative advanced breast cancer who experienced disease progression on first-line endocrine therapy plus CDK4/6 inhibition (Abstract 1098).
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047).
To learn more about this data, read a related article in Oncology and Therapy.
The ASCO Post Staff
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the primary prevention of hepatocellular carcinoma (HCC) in a pan-etiology high-risk cohort (Abstract 10522).
